Mucosal damage and neutropenia are required for Candida albicans dissemination
- PMID: 18282097
- PMCID: PMC2242836
- DOI: 10.1371/journal.ppat.0040035
Mucosal damage and neutropenia are required for Candida albicans dissemination
Abstract
Candida albicans fungemia in cancer patients is thought to develop from initial gastrointestinal (GI) colonization with subsequent translocation into the bloodstream after administration of chemotherapy. It is unclear what components of the innate immune system are necessary for preventing C. albicans dissemination from the GI tract, but we have hypothesized that both neutropenia and GI mucosal damage are critical for allowing widespread invasive C. albicans disease. We investigated these parameters in a mouse model of C. albicans GI colonization that led to systemic spread after administration of immunosuppression and mucosal damage. After depleting resident GI intestinal flora with antibiotic treatment and achieving stable GI colonization levels of C. albicans, it was determined that systemic chemotherapy with cyclophosphamide led to 100% mortality, whereas selective neutrophil depletion, macrophage depletion, lymphopenia or GI mucosal disruption alone resulted in no mortality. Selective neutrophil depletion combined with GI mucosal disruption led to disseminated fungal infection and 100% mortality ensued. GI translocation and dissemination by C. albicans was also dependent on the organism's ability to transform from the yeast to the hyphal form. This mouse model of GI colonization and fungemia is useful for studying factors of innate host immunity needed to prevent invasive C. albicans disease as well as identifying virulence factors that are necessary for fungal GI colonization and dissemination. The model may also prove valuable for evaluating therapies to control C. albicans infections.
Conflict of interest statement
Figures
Comment in
-
Host defense mechanisms in invasive candidiasis originating in the GI tract.Expert Rev Anti Infect Ther. 2008 Aug;6(4):441-5. doi: 10.1586/14787210.6.4.441. Expert Rev Anti Infect Ther. 2008. PMID: 18662111
References
-
- DiNubile MJ, Hille D, Sable CA, Kartsonis NA. Invasive candidiasis in cancer patients: Observations from a randomized clinical trial. J Infect. 2005;50:443–449. - PubMed
-
- Paulus SC, van Saene HK, Hemsworth S, Hughes J, Ng A, et al. A prospective study of septicaemia on a paediatric oncology unit: A three-year experience at The Royal Liverpool Children's Hospital, Alder Hey, UK. Eur J Cancer. 2005;41:2132–2140. - PubMed
-
- Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, et al. The direct cost and incidence of systemic fungal infections. Value Health. 2002;5:26–34. - PubMed
-
- Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37:1172–1177. - PubMed
-
- Wang SM, Yang YJ, Chen JS, Lin HC, Chi CY, et al. Invasive fungal infections in pediatric patients with leukemia: emphasis on pulmonary and dermatological manifestations. Acta Paediatr Taiwan. 2005;46:149–155. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
